HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
暂无分享,去创建一个
Suk Woo Nam | J. Eun | H. Bae | Jung Young Lee | S. Nam | Hanna Park | J. Noh | Y. G. Chang | Min Gyu Kim | K. Jung | Jeong kyu Kim | Ji Heon Noh | Hong Xie | Hanna Park | Kwang Hwa Jung | Jeong Kyu Kim | Jung Woo Eun | Hyun Jin Bae | Hong Jian Xie | Young Gyoon Chang | Jung Woo Eun | Hong Jian Xie | Jung Young Lee
[1] A. Bird,et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. , 1999, Genes & development.
[2] M. Carducci,et al. Acetylation and Histone Deacetylase Inhibitors in Cancer , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[3] A. Borczuk,et al. Expression of syndecan‐1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma , 2004, Cancer.
[4] O. Witt,et al. HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.
[5] Ivan V. Gregoretti,et al. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.
[6] P. Marks,et al. Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.
[7] R. Yarden,et al. BRCA1 interacts with components of the histone deacetylase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] E. Seto,et al. Histone deacetylases and cancer , 2007, Oncogene.
[9] John H. White,et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. , 2003, Molecular cell.
[10] J. Eun,et al. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. , 2005, Biochemical and Biophysical Research Communications - BBRC.
[11] Y. Yatabe,et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients , 2004, International journal of cancer.
[12] Charles A Powell,et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. , 2003, The American journal of pathology.
[13] J. Eun,et al. Increased Expression of Histone Deacetylase 2 is Found in Human Hepatocellular Carcinoma , 2006 .
[14] M. Salto‐Tellez,et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.
[15] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[16] E. Seto,et al. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.
[17] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[18] W. Weichert. HDAC expression and clinical prognosis in human malignancies. , 2009, Cancer letters.
[19] Tony Kouzarides,et al. Retinoblastoma protein recruits histone deacetylase to repress transcription , 1998, Nature.
[20] Suk Woo Nam,et al. Increased expression of histone deacetylase 2 is found in human gastric cancer , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[21] S. Minucci,et al. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.
[22] D. Saur,et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.
[23] Ping Zhu,et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.
[24] Delin Chen,et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.
[25] S. Schreiber,et al. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p , 1996, Science.
[26] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.